CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Inclusion Criteria:

1. Age greater than or equal to 18 at the time of enrollment
2. Documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after prior standard of care
3. Eastern Cooperative Oncology Group performance status 0 or 1
4. Adequate hematologic, renal, liver, cardiac and pulmonary organ function

Exclusion Criteria:

1. Prior therapy with an anti-CD19 targeting agent
2. Active or chronic graft versus host disease requiring therapy
3. Prior allogeneic stem cell transplantation
4. Central nervous system (CNS) lymphoma, prior CNS malignancy
5. Prior seizure disorder, cerebrovascular ischemia, dementia, cerebellar disease or autoimmune disease with CNS involvement.
6. Primary immunodeficiency
7. Current or expected need for systemic corticosteroid therapy
8. Current thyroid disorder. Hypothyroidism controlled with stable hormone replacement is permitted
9. Other malignancy within 2 years of study entry, except curatively treated malignancies or malignancies with low risk of recurrence
10. Unwillingness to follow extended safety monitoring